PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
From:
Vaccine. Author manuscript; available in PMC 2010 June 24.
Published in final edited form as:
Vaccine. 2009 June 24; 27(31): 4187–4195.
Published online 2009 May 9. doi: 10.1016/j.vaccine.2009.04.050

TABLE 1

Experimental H5N1 influenza vaccine groups for cross-protection studies

H5N1 vaccineaH5N1 challenge virusb
A/VN/1203/04A/WS/MG/244/05A/JWE/HK/1038/06
Adjuvanted vaccine
rg-A/VN/1203/04555
rg-A/HK/213/03555
rg-A/JWE/HK/1038/06555
Multiple-clade555
Control (1 X STE)555
Nonadjuvanted vaccine
rg-A/VN/1203/045-c-
rg-A/HK/213/035--
rg-A/JWE/HK/1038/065--
Multiple-clade5--
Control (1 X STE)5--

Note: Numbers indicate ferrets per experimental group.

aSingle-clade vaccines contained 7.5 μg HA per dose; multiple-clade vaccine contained 3.75 μg HA of each antigen per dose. All vaccines were given in 2 doses (0.5 ml each) injected intramuscularly at a 3-week interval. Multiple-clade vaccine contained rg-A/VN/1203/04 (clade 1), rg-A/HK/213/03 (clade 1), rg-A/JWE/HK/1038/06 (clade 2.2), and rg-A/WS/MG/244/05 (clade 2.3) antigens.
bOne week after the second (boost) dose of vaccine, ferrets were anesthetized with isoflurane and inoculated intranasally with 106 EID50 of a wild-type H5N1 challenge virus in 1 ml sterile PBS.
cChallenge experiments were not conducted.